<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860520</url>
  </required_header>
  <id_info>
    <org_study_id>5724</org_study_id>
    <nct_id>NCT02860520</nct_id>
  </id_info>
  <brief_title>Clinical Implication of Retinitis Pigmentosa Molecular Diagnostic Using High Throughput Sequencing.</brief_title>
  <acronym>RP-SEQ-HD</acronym>
  <official_title>Clinical Implication of the Molecular Diagnostic Retinitis Pigmentosa Molecular Diagnostic Using High Throughput Sequencing (RP-SEQ-HD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The retinitis pigmentosa (RP) are genetic conditions that cause retinal degeneration leading
      to severe low vision and is the leading cause of consultation in reference centers dedicated
      to the ophthalmic genetics. These rare diseases are characterized by a triple heterogeneity
      (clinical, genetic and molecular), which made them unreachable by traditional molecular
      diagnostic sequencing technology by the large number of genes to be tested (&gt; 190).

      The advent of high-throughput sequencing (NGS) and targeted capture has opened unexpected
      possibilities of investigation and ultimately to improve the care of patients. This project
      aims to study the genetic and molecular epidemiology of an interregional french (grand EST)
      cohort of patients. Patients receive a detailed retinal phenotype (visual acuity, visual
      field, photographs of the fundus and ERG). Their DNA will be analyzed by NGS targets the 190
      known genes (https://sph.uth.edu/retnet/).

      This research will provide a molecular epidemiological cohort study compared to prior
      publications on the frequency of genes involved. The benefit for patients is important to:
      establish a mode of transmission of the disease and optimize genetic counseling (currently
      very empirical); establish phenotype-genotype correlations in the French population (very few
      studies to date) and from the data of international literature; identify patients likely to
      be included in future therapeutic protocols of research; identify patients with significant
      potential for future projects to identify new genes.

      The primary purpose of the protocol is to use high throughput sequencing to identify
      pathogenic variants in genes involved in RP.

      The secondary purposes will be the following:

        -  Determining the diagnostic yield

        -  Study the genotype-phenotype correlation.

      The secondary purposes will be the following:

        -  Determining the diagnostic yield

        -  Study the genotype-phenotype correlation
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with a deleterious mutation</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of positive diagnostic</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of gene with a genotype-phenotype correlation</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an RP and/or having a family history of RP
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject of both sex, aged at least 2 years, being diagnosed with an RP, and/or having
             a family history of RP

          -  Informed about the results of the preliminary medical visit, or which (s) holder (s)
             parental authority or the guardian / curator has (have) was (been) informed

          -  Informed consent signed

          -  Affiliation to the French health system

        Exclusion Criteria:

          -  The patient does not want to participate to the protocol

          -  Intercurrent diseases do not allow the practice of tests provided for this protocol

          -  Phenocopy

          -  Subject excluded or being excluded by another protocol

          -  Subject in emergency case

          -  Subject under judicial protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène DOLLFUS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hélène DOLLFUS, MD</last_name>
    <phone>33.3.88.12.81.19</phone>
    <email>helene.dollfus@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean MULLER, PHD</last_name>
    <phone>33.3.69.55.11.66</phone>
    <email>jean.muller@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Ophtalmologie CHU Hôpital Général</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine CREUZOT-GARCHER, MD</last_name>
      <phone>33.3.80.29.37.56</phone>
      <email>catherine.creuzot-garcher@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine CREUZOT-GARCHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain BRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Ophtalmologie, Hôpital Robert Debré, CHR</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carl ARNDT, MD</last_name>
      <phone>33.3.26.78.77.20</phone>
      <email>prarndt@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carl ARNDT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique GAILLARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affections Rares en Génétique Ophtalmologique (CARGO) Hôpital Civil, Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène DOLLFUS, MD</last_name>
      <phone>33.3.88.11.67.53</phone>
      <email>helene.dollfus@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean MULLER, PHD</last_name>
      <phone>03.69.55.11.66</phone>
      <email>jean.muller@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Hélène DOLLFUS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yaumara PERDOMO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Ophtalmologie, CHU BRABOIS</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karine ANGIOI-DUPREZ, MD</last_name>
      <phone>33.3.15.30.39</phone>
      <email>k.angioi-duprez@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Karine ANGIOI-DUPREZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno LEHEUP, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe JONVEAUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>August 11, 2016</last_update_submitted>
  <last_update_submitted_qc>August 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinitis pigmentosa:</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

